ClinicalTrials.gg
Not yet recruitingNCT07949708UNIVOUpdated Nov 19, 2026

Extra Virgin Olive Oil Versus Olive Oil on Health Status

An interventional study of Extra virgin olive oil and Olive oil in Healthy Nutrition, sponsored by University of Barcelona. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Barcelona · Not applicable, Interventional, and Prevention

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Extra virgin olive oil (EVOO) is a key component of the Mediterranean diet and is widely recognized for its beneficial health effects, largely attributed to its high content of bioactive compounds such as polyphenols and monounsaturated fatty acids. However, in real-life conditions, olive oil is frequently consumed after culinary processing (e.g., frying, baking), which may alter its chemical composition and biological properties. In contrast, regular olive oil (OO) undergoes industrial processing that reduces its content of bioactive compounds and may generate potentially harmful substances. Despite increasing evidence supporting the health benefits of EVOO, there is a lack of clinical studies evaluating how culinary processing influences the metabolic response to different types of olive oil in humans. Furthermore, no specific metabolic biomarkers are currently available to distinguish the intake of thermally processed EVOO versus OO. Therefore, this study aims to identify and validate a distinctive metabolic fingerprint associated with the consumption of EVOO and OO after cooking, using a randomized, controlled, crossover, dose-response clinical trial in healthy adults. The findings will contribute to a better understanding of the health implications of culinary practices involving olive oil and support evidence-based dietary recommendations.

Read the detailed description

This study is a randomized, controlled, crossover, acute dose-response nutritional intervention designed to evaluate the metabolic effects of consuming cooked extra virgin olive oil (EVOO) compared to olive oil (OO) in healthy adults. A total of 40 participants (50% women), aged 18 to 70 years, will be recruited. Each participant will serve as their own control and will undergo six intervention periods corresponding to three different doses (15 mL, 30 mL, and 45 mL) of two types of olive oil (EVOO and OO), all subjected to standardized culinary processing (sautéing). Each intervention will last one day (approximately 4 hours) and will be separated by a 4-week washout period to minimize carryover effects.

Prior to each intervention, participants will follow a short dietary restriction period to limit intake of polyphenol-rich foods and olive oil-containing products. On each intervention day, participants will attend the clinical center after an overnight fast. Biological samples will be collected at baseline and at multiple postprandial time points (15, 30, 60, 120, 180, and 240 minutes, and 24 hours). The primary outcome is the identification of a metabolic fingerprint based on metabolomic and lipidomic profiles obtained from plasma and urine samples using advanced analytical platforms, specifically ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Both targeted and untargeted approaches will be applied to detect and quantify metabolites associated with each intervention.

Secondary outcomes include the assessment of inflammatory biomarkers (e.g., interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP)), lipid profile, including total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, blood pressure, anthropometric parameters, dietary intake, and physical activity levels. The study will also incorporate a sex-based analytical approach to explore potential differences in metabolic responses between men and women. Overall, this multidisciplinary study integrates clinical, nutritional, and omics-based methodologies to provide novel insights into the metabolic impact of culinary processed olive oils under real-world conditions.

02

Conditions studied

  • Healthy Nutrition

Keywords

  • Hydroxytyrosol
  • Oleic acid
  • Extra virgin olive oil
03

In context

Lead sponsor

University of Barcelona is the lead sponsor of 100 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults (defined as an individual with no chronic or acute pathologies and whose biochemical parameters are within a normal range)
  • : \<27 kg/m2
  • Age: ≥18 to 70 years old.

Exclusion criteria

Exclusion Criteria:

  • Smokers
  • Presence of cardiovascular, hepatic, renal, or metabolic disease
  • Mental disorders (e.g., depression, dementia, autism, etc.)
  • Cardiovascular abnormalities in cholesterol, triglycerides, glucose, etc.
  • Regular use of antibiotics, vitamin supplements, , or nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Adherence to restrictive diets or dietary patterns that may interfere with lipid metabolism
  • Excessive alcohol consumption (>30 grams/day for men and >20 grams/day for women)
  • Pregnancy or breastfeeding
  • Participation in another ongoing research study
  • Intolerance or allergy to olive oil or wheat
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Extra virgin olive oil (EVOO)

    After a one-day run-in period (avoiding polyphenol-rich foods and olive oil), participants will receive, in a randomized, balanced-block design, the six intervention conditions (three doses x two types of cooked oil). Each condition consists of one day of intervention, during which the corresponding dose of oil prepared using cooking methods (sautéing) is administered. Intervention periods will be separated by four-week washouts. All participants will receive all six conditions (extra virgin olive oil (EVOO) and regular olive oil (OO) in all three doses).

    Other: Extra virgin olive oil

  • Active comparator
    Regular olive oil

    Participants will receive the exact same six intervention conditions as the previous arm, but in a different sequence order (also randomized by balanced blocks). Each participant acts as their own control and receives all conditions, including a dose-response of extra virgin olive oil (EVOO) and regular olive oil (OO).

    Other: Olive oil

Interventions

  • OtherExtra virgin olive oil

    Participants will consume a pre-established dose (15, 30, or 45 mL) of sautéed extra virgin olive oil (EVOO) in a randomized order.

  • OtherOlive oil

    Participants will consume a pre-established dose (15, 30, or 45 mL) of sautéed regular olive oil (OO) in a randomized order.

06

What researchers measure

Primary outcomes

  1. Change from baseline in plasma metabolite and lipid concentrations following extra virgin olive oil (EVOO) and control olive oil (OO) intake.

    Targeted and untargeted metabolomic and lipidomic profiling in plasma samples will be analyzed via ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Changes in peak areas and concentrations of identified metabolites and lipids (including phenolic compounds and phase II metabolites) will be measured and reported.

    Time frame: Baseline (0 minutes), and post-intervention at 15 minutes, 30 minutes, 60 minutes, 120 minutes, 180 minutes, and 240 minutes.

  2. Change from baseline in urinary metabolite concentrations following extra virgin olive oil (EVOO) and control olive oil (OO) intake.

    Targeted and untargeted metabolomic profiling of accumulated urine samples will be analyzed via ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Total excreted amounts and relative abundances of phenolic metabolites and endogenous compounds will be measured and reported.

    Time frame: Baseline (0 hours), and accumulated urine collection intervals from 0 to 3 hours, 3 to 5 hours, 5 to 12 hours, and 12 to 24 hours post-intervention.

Secondary outcomes

  1. Change from baseline in body weight following extra virgin olive oil (EVOO) and control olive oil (OO) intervention phases

    Body weight will be measured using a calibrated scale and recorded in kilograms (kg).

    Time frame: Baseline and at the end of each intervention phase (1 day).

  2. Change from baseline in body mass index (BMI) following extra virgin olive oil (EVOO) and control olive oil (OO) intervention phases

    BMI will be calculated as body weight (kg) divided by height squared (m²) and expressed as kg/m²

    Time frame: Baseline and at the end of each intervention phase (1 day).

  3. Change from baseline in waist circumference following extra virgin olive oil (EVOO) and control olive oil (OO) intervention phases.

    Waist circumference will be measured in triplicate using an inextensible tape measure and recorded in centimeters (cm).

    Time frame: Baseline and at the end of each intervention phase (1 day).

  4. Change from baseline in body fat percentage following extra virgin olive oil (EVOO) and control olive oil (OO) intervention phases.

    Body fat percentage will be measured using a bioelectrical impedance analysis (BIA) device and expressed as a percentage (%).

    Time frame: Baseline and after each 1-day intervention period, through study completion (up to 24 weeks).

  5. Change from baseline in Mediterranean diet adherence score following extra virgin olive oil (EVOO) and control olive oil (OO) intervention phases.

    Participants will complete a validated Mediterranean Diet Adherence Screener (MEDAS) questionnaire (scores range from 0 to 14; higher scores indicate greater adherence). This questionnaire has been validated for the Spanish population and assesses adherence to the Mediterranean diet. Additionally, participants will complete a 3-day food diary to assess overall food-group intake frequency.

    Time frame: Baseline and after each 1-day intervention dose (up to 24 weeks).

  6. Change from baseline in total energy and nutrient intake following extra virgin olive oil (EVOO) and control olive oil (OO) intervention phases.

    Daily energy (kcal/day) and macro- and micronutrient intake (g/day or mg/day) will be assessed using a 7-day dietary recall and analyzed with the Professional Nutritional Calculation Program (PCN Pro) software.

    Time frame: Baseline and after each 1-day intervention period, through study completion (up to 24 weeks).

  7. Change from baseline in plasma lipid profile following extra virgin olive oil (EVOO) and control olive oil (OO) intervention phases.

    Plasma concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides (expressed in mg/dL) will be determined using molecular absorption spectrometry.

    Time frame: Baseline and at the end of each intervention phase.

  8. Change from baseline in systolic and diastolic blood pressure following extra virgin olive oil (EVOO) and control olive oil (OO) intervention phases.

    Systolic and diastolic blood pressure (expressed in mmHg) will be measured in triplicate after 5 minutes of rest using a validated automatic sphygmomanometer.

    Time frame: Baseline and at the end of each intervention phase.

  9. Change from baseline in plasma inflammatory biomarker concentrations following extra virgin olive oil (EVOO) and control olive oil (OO) intake.

    Plasma concentrations of tumor necrosis factor-alpha (TNF-alpha, pg/mL), C-reactive protein (CRP, mg/dL), and interleukin-6 (IL-6, pg/mL) will be quantified using immunoenzymatic assays.

    Time frame: Baseline (0 minutes) and 24 hours after consumption of the olive oil dose.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Nov 19, 2026
StartEst.
Jan 11, 2027
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949708
Responsible party
Rosa M Lamuela-Raventós (Full Professor, University of Barcelona) — Principal investigator
First posted
Nov 19, 2026
Start date
Jan 11, 2027 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Rosa M Lamuela-Raventós, PhD
Contact
lamuela@ub.edu
93403484

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion